Lupin gets FDA approval for Cefdinir suspension

By Elaine Rigoli

Tampa, Fla., June 2 - Lupin Ltd. has received Food and Drug Administration approval for Cefdinir suspension 125 mg/5 mL, administered orally to treat a wide variety of bacterial infections.

Abbott markets Cefdinir under the Omnicef brand name.

As per IMS data, last year's sales of Omnicef suspension 125 mg/5mL was $137 million and the combined sales for capsules and suspensions was $634 million.

Lupin said it is the first company to receive approval for Cefdinir in both capsule and suspension forms.

Lupin is an international pharmaceutical company based in Mumbai, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.